CN105307499B - 用于肿瘤毒性和mri的靶向可咯 - Google Patents

用于肿瘤毒性和mri的靶向可咯 Download PDF

Info

Publication number
CN105307499B
CN105307499B CN201480025009.6A CN201480025009A CN105307499B CN 105307499 B CN105307499 B CN 105307499B CN 201480025009 A CN201480025009 A CN 201480025009A CN 105307499 B CN105307499 B CN 105307499B
Authority
CN
China
Prior art keywords
pharmaceutical composition
corroles
targeted
nanoparticles
mri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480025009.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105307499A (zh
Inventor
拉里·K·梅迪纳-考维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to CN201810246983.5A priority Critical patent/CN108451930A/zh
Publication of CN105307499A publication Critical patent/CN105307499A/zh
Application granted granted Critical
Publication of CN105307499B publication Critical patent/CN105307499B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480025009.6A 2013-05-08 2014-05-08 用于肿瘤毒性和mri的靶向可咯 Expired - Fee Related CN105307499B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810246983.5A CN108451930A (zh) 2013-05-08 2014-05-08 用于肿瘤毒性和mri的靶向可咯

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08
US61/821,106 2013-05-08
PCT/US2014/037234 WO2014182868A1 (en) 2013-05-08 2014-05-08 Targeting corroles for tumor toxicity and mri

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810246983.5A Division CN108451930A (zh) 2013-05-08 2014-05-08 用于肿瘤毒性和mri的靶向可咯

Publications (2)

Publication Number Publication Date
CN105307499A CN105307499A (zh) 2016-02-03
CN105307499B true CN105307499B (zh) 2018-04-27

Family

ID=51864925

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810246983.5A Withdrawn CN108451930A (zh) 2013-05-08 2014-05-08 用于肿瘤毒性和mri的靶向可咯
CN201480025009.6A Expired - Fee Related CN105307499B (zh) 2013-05-08 2014-05-08 用于肿瘤毒性和mri的靶向可咯

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810246983.5A Withdrawn CN108451930A (zh) 2013-05-08 2014-05-08 用于肿瘤毒性和mri的靶向可咯

Country Status (16)

Country Link
US (2) US9757386B2 (enExample)
EP (2) EP3730155A1 (enExample)
JP (1) JP6640715B2 (enExample)
KR (1) KR20160008523A (enExample)
CN (2) CN108451930A (enExample)
AU (2) AU2014262653B2 (enExample)
CA (1) CA2910030A1 (enExample)
DK (1) DK2993983T3 (enExample)
ES (1) ES2791043T3 (enExample)
IL (1) IL265935B (enExample)
MX (1) MX2015015434A (enExample)
PL (1) PL2993983T3 (enExample)
PT (1) PT2993983T (enExample)
RU (1) RU2674146C2 (enExample)
WO (1) WO2014182868A1 (enExample)
ZA (1) ZA201508092B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
KR102115630B1 (ko) 2012-08-03 2020-05-27 세다르스-신나이 메디칼 센터 약물 전달 단백질의 수송-증진 돌연변이체의 단리
JP6640715B2 (ja) 2013-05-08 2020-02-05 セダーズ−シナイ メディカル センター 腫瘍毒性に対する標的コロールおよびｍｒｉ
CN106413738B (zh) 2014-01-17 2020-12-29 席德-西奈医疗中心 受体靶向构造物和其使用
CN106170305A (zh) 2014-04-04 2016-11-30 席德-西奈医疗中心 用her3靶向纳米粒子靶向曲妥珠单抗抗性her2+乳腺癌
EP3687998A4 (en) * 2017-08-31 2021-05-19 Technion Research & Development Foundation Limited CORROL COMPOSITIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180872A1 (en) * 2001-07-02 2004-09-16 Zeev Gross Method for the preparation of selectively-substituted corroles and new substituted corroles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US8791099B2 (en) * 2007-08-28 2014-07-29 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
US20110098262A1 (en) * 2008-01-31 2011-04-28 Yondim Moussa B H Corroles for neuroprotection and neurorescue
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
JP2014521738A (ja) * 2011-08-15 2014-08-28 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド コロールおよびスタチンの併用
KR102115630B1 (ko) 2012-08-03 2020-05-27 세다르스-신나이 메디칼 센터 약물 전달 단백질의 수송-증진 돌연변이체의 단리
JP6640715B2 (ja) 2013-05-08 2020-02-05 セダーズ−シナイ メディカル センター 腫瘍毒性に対する標的コロールおよびｍｒｉ
CN106413738B (zh) 2014-01-17 2020-12-29 席德-西奈医疗中心 受体靶向构造物和其使用
CN106170305A (zh) 2014-04-04 2016-11-30 席德-西奈医疗中心 用her3靶向纳米粒子靶向曲妥珠单抗抗性her2+乳腺癌
AU2017271662A1 (en) 2016-05-27 2018-12-06 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180872A1 (en) * 2001-07-02 2004-09-16 Zeev Gross Method for the preparation of selectively-substituted corroles and new substituted corroles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Multimodality Imaging In Vivo for Preclinical Assessment of Tumor-Targeted Doxorubicin Nanoparticles;Jae Youn Hwang et al;《PLoS ONE》;20120430;第7卷(第4期);第1页第1-3段 *
Tumor detection and elimination by a targeted gallium corrole;Hasmik Agadjanian et al;《PNAS》;20090414;第106卷(第15期);第6105页第1栏第3段 *

Also Published As

Publication number Publication date
AU2018250401A1 (en) 2018-11-08
DK2993983T3 (da) 2020-05-18
US10709801B2 (en) 2020-07-14
CA2910030A1 (en) 2014-11-13
EP2993983A1 (en) 2016-03-16
ES2791043T3 (es) 2020-10-30
PL2993983T3 (pl) 2020-09-07
PT2993983T (pt) 2020-05-22
ZA201508092B (en) 2017-02-22
EP2993983A4 (en) 2017-01-11
IL265935A (en) 2019-05-30
WO2014182868A1 (en) 2014-11-13
AU2014262653A1 (en) 2015-11-12
KR20160008523A (ko) 2016-01-22
MX2015015434A (es) 2016-03-15
CN108451930A (zh) 2018-08-28
US9757386B2 (en) 2017-09-12
RU2015152033A (ru) 2017-06-16
EP2993983B1 (en) 2020-03-25
AU2014262653B2 (en) 2018-07-26
CN105307499A (zh) 2016-02-03
JP2016526021A (ja) 2016-09-01
HK1221870A1 (en) 2017-06-16
RU2674146C2 (ru) 2018-12-07
US20170281802A1 (en) 2017-10-05
US20140335025A1 (en) 2014-11-13
AU2018250401B2 (en) 2020-06-11
RU2015152033A3 (enExample) 2018-04-25
JP6640715B2 (ja) 2020-02-05
EP3730155A1 (en) 2020-10-28
IL265935B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CN105307499B (zh) 用于肿瘤毒性和mri的靶向可咯
CN103608139B (zh) 表面改性的重金属纳米粒子、组合物及其用途
Wei et al. OFF–ON nanodiamond drug platform for targeted cancer imaging and therapy
Jibin et al. Nanohybrids of magnetically intercalated optical metamaterials for magnetic resonance/Raman imaging and in situ chemodynamic/photothermal therapy
WO2001052868A9 (en) Combinations for treating neoplasms
Wang et al. Potentiated cytosolic drug delivery and photonic hyperthermia by 2D free-standing silicene nanosheets for tumor nanomedicine
US20230390394A1 (en) Bismuth-Gadolinium Nanoparticles
Nasiri et al. Targeted delivery of bromelain using dual mode nanoparticles: synthesis, physicochemical characterization, in vitro and in vivo evaluation
WO2013095736A2 (en) Gold-in-silicon nanoassembly for thermal therapy and methods of use
Li et al. The construction of the novel magnetic prodrug Fe 3 O 4@ DOX and its antagonistic effects on hepatocarcinoma with low toxicity
Nasr Azadani et al. Nanoparticles in Cancer Theranostics: Focus on Gliomas
Burgum et al. Considerations for the human health implications of nanotheranostics
HK1260403A1 (en) Targeting corroles for tumor toxicity and mri
Duan et al. Magnetic Navigation of Spatiotemporally Synergistic Delivery to Potentiate Sonodynamic Therapy of Orthotopic Pancreatic Carcinoma
CN110862546B (zh) 一种甲氨蝶呤金属配位聚合物及其制备方法和应用
HK1221870B (en) Targeting corroles for tumor toxicity and mri
CN118924907B (zh) 一种多功能dna纳米球及其制备方法和应用
He et al. An optical/magnetic imaging nanoplatform-mediated convection-enhanced delivery of oxaliplatin for glioma treatment
CN120267849A (zh) 一种靶向双硫死亡的载6-氨基烟酰胺纳米材料及其制备方法和在卵巢癌中的应用
Wu et al. Microglial Membrane Camouflaged Nano‐AUTAC to Promote Autophagy‐Mediated β‐Catenin Degradation for Reducing TMZ Resistance in Glioblastoma
CN120168657A (zh) 一种肿瘤线粒体靶向的双重铜耗竭纳米海绵及其制备方法和应用
CN120837683A (zh) Rvg29修饰的双响应载药纳米颗粒及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180427